Research ExplorerPublicationsNeue Aspekte in der Therapie von Schilddrüsenkarzinomen

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Standard

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen : Highlights vom ASCO-Kongress 2018. / Möckelmann, N; Münscher, A.

In: HNO, Vol. 66, No. 12, 12.2018, p. 896-900.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Möckelmann, N & Münscher, A 2018, 'Neue Aspekte in der Therapie von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2018', HNO, vol. 66, no. 12, pp. 896-900. https://doi.org/10.1007/s00106-018-0589-z

APA

Möckelmann, N., & Münscher, A. (2018). Neue Aspekte in der Therapie von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2018. HNO, 66(12), 896-900. https://doi.org/10.1007/s00106-018-0589-z

Vancouver

Möckelmann N, Münscher A. Neue Aspekte in der Therapie von Schilddrüsenkarzinomen: Highlights vom ASCO-Kongress 2018. HNO. 2018 Dec;66(12):896-900. https://doi.org/10.1007/s00106-018-0589-z

Bibtex

@article{9cb2ac2feb924739bb0d2b71544a2977,
title = "Neue Aspekte in der Therapie von Schilddr{\"u}senkarzinomen: Highlights vom ASCO-Kongress 2018",
abstract = "Whereas surgical treatment of thyroid carcinoma plays an important role especially in the early stages, a multimodal approach is pursued in the palliative setting, which, in addition to classical chemotherapy primarily involves treatment with tyrosine kinase inhibitors. An analysis of clinical trials and studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 is presented. In particular, studies on the treatment of radioiodine-refractory differentiated thyroid cancer, anaplastic thyroid cancer and immunotherapy were selected and analyzed. Clinically and preclinically relevant studies are presented and critically interpreted in this review.",
keywords = "Humans, Immunologic Factors, Immunotherapy, Iodine Radioisotopes/therapeutic use, Thyroid Neoplasms/therapy",
author = "N M{\"o}ckelmann and A M{\"u}nscher",
year = "2018",
month = dec,
doi = "10.1007/s00106-018-0589-z",
language = "Deutsch",
volume = "66",
pages = "896--900",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

T2 - Highlights vom ASCO-Kongress 2018

AU - Möckelmann, N

AU - Münscher, A

PY - 2018/12

Y1 - 2018/12

N2 - Whereas surgical treatment of thyroid carcinoma plays an important role especially in the early stages, a multimodal approach is pursued in the palliative setting, which, in addition to classical chemotherapy primarily involves treatment with tyrosine kinase inhibitors. An analysis of clinical trials and studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 is presented. In particular, studies on the treatment of radioiodine-refractory differentiated thyroid cancer, anaplastic thyroid cancer and immunotherapy were selected and analyzed. Clinically and preclinically relevant studies are presented and critically interpreted in this review.

AB - Whereas surgical treatment of thyroid carcinoma plays an important role especially in the early stages, a multimodal approach is pursued in the palliative setting, which, in addition to classical chemotherapy primarily involves treatment with tyrosine kinase inhibitors. An analysis of clinical trials and studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 is presented. In particular, studies on the treatment of radioiodine-refractory differentiated thyroid cancer, anaplastic thyroid cancer and immunotherapy were selected and analyzed. Clinically and preclinically relevant studies are presented and critically interpreted in this review.

KW - Humans

KW - Immunologic Factors

KW - Immunotherapy

KW - Iodine Radioisotopes/therapeutic use

KW - Thyroid Neoplasms/therapy

U2 - 10.1007/s00106-018-0589-z

DO - 10.1007/s00106-018-0589-z

M3 - SCORING: Review

C2 - 30402812

VL - 66

SP - 896

EP - 900

JO - HNO

JF - HNO

SN - 0017-6192

IS - 12

ER -